drug
Eylea
Marketedupdated 6mo agoby $REGN REGENERON PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval40 co-mentions · 15 sources
- drugEYLEA HD32 co-mentions · 15 sources
- drugaflibercept biosimilar15 co-mentions · 10 sources
- drugYESAFILI14 co-mentions · 7 sources
- drugOPUVIZ8 co-mentions · 4 sources
- drugENZEEVU6 co-mentions · 3 sources
- companySamsung Bioepis Co Ltd4 co-mentions · 4 sources
- companySandoz Inc3 co-mentions · 3 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Eylea
- phase2RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
- phase3A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
- phase3A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
- phase2A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
- —An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
- phase3CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
- phase3Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
- phase3A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
News(10)
- J&J bets $2.2B on Ollin’s vision loss drugThe deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.biopharma_dive · 20h ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecificJohnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.fiercebiotech · 1d ago
- Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceAstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.biopharma_dive · 14d ago
- Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deckRegeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…biospace · 17d ago
- EyePoint will halve workforce, end pivotal wet AMD trials early following second failEyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shiftin…biospace · 28d ago
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingThe latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.biopharma_dive · 1mo ago
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 1mo ago
- Kodiak skyrockets on positive study data for 2 eye drugsThe Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.biopharma_dive · 1mo ago
- Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitorKodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…endpoints · 1mo ago
- Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trialKodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.biospace · 1mo ago
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that